References

• Al-Awadhi, M., Ahmad, S., & Iqbal, J. (2021). Current Status and the Epidemiology of Malaria in the Middle East Region and Beyond. Microorganisms, 9(2), 338.
• Auburn, S., Cheng, Q., Marfurt, J., & Price, R. N. (2021). The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools. PLoS medicine, 18(4), e1003560.
• Baird, K. (2015). Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. Pathogens and global health, 109(3), 93-106.
• Chu, C. S., & White, N. J. (2021). The prevention and treatment of Plasmodium vivax malaria. PLoS medicine, 18(4), e1003561.
• Douglas, N. M., Pontororing, G. J., Lampah, D. A., Yeo, T. W., Kenangalem, E., Poespoprodjo, J. R., & Price, R. N. (2014). Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC medicine, 12(1), 1-13.
• Joshi, H., Prajapati, S. K., Verma, A., Kang'a, S., & Carlton, J. M. (2008). Plasmodium vivax in India. Trends in parasitology, 24(5), 228-235.
• Kondrashin, A., Baranova, A. M., Ashley, E. A., Recht, J., White, N. J., & Sergiev, V. P. (2014). Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malaria journal, 13(1), 1-16.
• Lima-Junior, J. D. C., & Pratt-Riccio, L. R. (2016). Major Histocompatibility Complex and Malaria: Focus on Plasmodium vivax Infection. Frontiers in Immunology, 7.
• Lorenz von Seidlein, I. D. (2021). Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure.
• Mouchet, J. (1988). Agriculture and vector resistance. International Journal of Tropical Insect Science, 9(3), 297-302.
• Ngufor, C., Fagbohoun, J., Critchley, J., N'Guessan, R., Todjinou, D., Malone, D., & Rowland, M. (2017). Which intervention is better for malaria vector control: insecticide mixture long-lasting insecticidal nets or standard pyrethroid nets combined with indoor residual spraying? Malaria journal, 16(1), 1-9.
• Payne, R. O., Silk, S. E., Elias, S. C., Milne, K. H., Rawlinson, T. A., Llewellyn, D., & Draper, S. J. (2017). Human vaccination against Plasmodium vivax Duffy-binding protein induces strain- transcending antibodies. JCI insight, 2(12).
• Poespoprodjo, J. R., Fobia, W., Kenangalem, E., Lampah, D. A., Hasanuddin, A., Warikar, N., & Price, R. N. (2009). Vivax malaria: a major cause of morbidity in early infancy. Clinical Infectious Diseases, 48(12), 1704-1712.
• Protopopoff, N., Mosha, J. F., Lukole, E., Charlwood, J. D., Wright, A., Mwalimu, C. D., & Rowland, M. (2018). Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomized controlled, two-by-two factorial design trial. The Lancet, 391(10130), 1577- 1588.
• Pukrittayakamee, S., Vanijanonta, S., Chantra, A., Clemens, R., & White, N. J. (1994). Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. Journal of Infectious Diseases, 169(4), 932-935.
• Rahimi, B. A., Thakkinstian, A., White, N. J., Sirivichayakul, C., Dondorp, A. M., & Chokejindachai, W. (2014). Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malaria journal, 13(1), 1-10.
• Smithuis, F., Kyaw, M. K., Phe, O., Win, T., Aung, P. P., Oo, A. P. P., & White, N. J. (2010). Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open- label randomized trial. The Lancet infectious diseases, 10(10), 673-681.
• World Health Organization. (2015). Guidelines for the treatment of malaria. World Health Organization.